Michael F. Para, MD
Professor of Internal Medicine
and Molecular Virology, Immunology, and Medical Genetics
Para MF, Kalish LA, Collier AC, Pollard R, Kumar P, Wallach F, Mintz L, and Drew WL for the VATS Study Group. Qualitative and Quantitative PCR Measures of CMV in Patients with Advanced HIV Infection Requiring Transfusion. J Acquire Immun Defic Syndrom 2001;26:320-325.
Smith BA, Neidig JL, Nickel JT, Mitchell GL, Para MF, Fass.RJ. Aerobic exercise training: Effects on parameters associated with fatigue, dyspnea, weight and body composition in HIV-1 infected adults. AIDS 2001;15:693-701
Para MF, Kalish LA, Collier AC, Murphy EL, Drew WL. Correlates of change in CMV viremia in Patients with Advanced HIV Infection Requiring Transfusion. J Infect Dis June 1, 2001; 183:1673-1678.
Albrecht MA, Bosch RJ, Dehlinger M, Katzenstein DA, Liou SH, Eron J, Para MF, Valdez H, Kessler H, Hammer SM. Virologic efficacy of nelfinavir and/or efavirenz with new nucleoside therapy in HIV-infected individuals with prior nucleoside analog exposure. N Engl J Med , August 9; 345:398, 2001.
Murphy EL, Kalish LA, Para MF, Kumar PN, Wallach FR, Collier AC, Assmann SF, Flanigan TP, Mintz L, Nemo GJ. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. July 3, 2001, Ann Intern Med 2001; 135:17—26.
Knudtson E, Para M, Boswell H, and Fan-Havard P. Drug rash, eosinophilia, systemic syndrome and renal toxicity with nevirapine-containing regimen in a pregnant patient with HIV. Obstet Gynecol 2003;101:1094-1097
Picciano JF. Celum C, Whittington W, Buchbinder S, Bartholow B, McKirnan D, Mayer K. Para MF, Morris M. Sexual risk-taking behavior among phase III HIV vaccine efficacy trial participants and a control group: Project VISION. Submitted
Bartholow, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, McKirnan DJ, Creticos C, Orozco-Cronin P, Popovic V, and Mastro TD, for the VISION/VAX004 Study HIV Sexual Risk Behavior over 36-Months of Follow-up in the World’s First HIV Vaccine Efficacy Trial. BN J Acquir Immune Defic Syndr 2005; 39:90-101
Smith PF, DiCenzo R, Forrest A, Shelton M, Friedland G, Michael F. Para MF, Pollard R, Fischl M, DiFrancesco R, Morse GD. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clinical Pharmacokinet 2005;44: 99-109
Gurwith,M, Gilbert P, Berman P, Flynn, N, Forthal D, Harro C, Heyward, W, Hudgens M, Judson F, Mayer K, Metch B, Para, MF, PopovicV, Self, S., and Francis DP, for the rgp 120 HIV Vaccine Study Group*. Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection J Infect Dis. 2005 Mar 1;191(5):654-65
Morse GD, Rosenkranz S, Para MF, Segal Y DiFrancesco R Adams E Brizz B, Yarasheski K, Reichman R, and the ACTG 5043 Protocol Team. Amprenavir and Efavirenz Pharmacokinetics Before and After the Addition of Nelfinavir, Indinavir, Ritonavir or Saquinavir Antimicrob. Agents Chemother. 2005,49:3373-81
Fletcher C, Swindells S, Para M. Nonnucleoside Analogue Reverse Transcriptase Inhibitors chapter in Antimicrobial Therapy and Vaccines Volume II Antimicrobial Agents 2005 editors Yu V, Edwards G, McKinnon P, Peloquin, Morse, Potoski. Page 817.
Rosenkranz SL, Yarasheski KE, Para MF, Reichman R, Morse GD, and the ACTG 5043 Protocol Team. Brief efavirenz plus protease inhibitor exposure raises serum lipids without affecting glycemic parameters in HIV-seronegative subjects. Submitted. To AIDS
